Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
The archive
Page 162 of 170 of this archive, newest first.
TRIUMPH-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
What a laboratory knows about the material it receives
The condition on arrival is recorded by some services and not others, and it is one of the more informative lines in a report.
A vial can be 99.4 per cent pure and not sterile in the same afternoon
Every certificate circulating in this market answers a question about molecules. Almost none answers a question about organisms, pyrogens, or the integrity of the seal.
Calder Vale Peptides of Skipton closes after 15 years
A proper account of an operation that existed, and of what closing it cost.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
A supplier suspends shipping to South Korea after 17 consecutive customs detentions
The route did not close because of a rule about peptides.
MKM declines, for the 19th time, to name its synthesis house
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Who signed this, and what did they undertake by signing it
Somebody has to be answerable for a release document. On most certificates in this market, nobody is named at all.
In-use stability is a separate study, and almost nobody has done it
An in-use period is established by a dedicated study on a specific formulation in a specific container at a specific concentration. Borrowing one from a marketed product is…
A needle is a single-use instrument
For licensed products the in-use period is established by stability data. For a peptide reconstituted at home there is no such data, and the honest answer is that nobody…
Calder Vale Peptides of Skipton enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Independent analysis puts a SSA exenatide lot at 97.3%, against 93.3% on the certificate
The supplier has not disputed the finding. It has not explained the gap either.
Wuhan export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
The 24-day notice: how a compounding wind-down works in Japan
The document is four pages. Three of them are about dates.
Why the bone question is harder than the muscle question
What the Journal would want measured before treating this as settled in either direction.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A supplier suspends shipping to South Korea after 6 consecutive customs detentions
The route did not close because of a rule about peptides.
Severity grading, and the gap between a grade and an experience
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
Oxidation, and the peroxide that came in with the surfactant
The sequence predicts the failure mode. A methionine predicts oxidation; an asparagine followed by a glycine predicts deamidation; a cysteine predicts disulphide scrambling.
What a 40% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
The United Kingdom caps exenatide prescribing to 20 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Zhuhai: 18 posters, one theme
Reported from the sessions, and from the two hours afterwards.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
Reading the semaglutide composition data without the press release
The composition data comes from imaging substudies enrolling a few score participants at selected sites. It is the best evidence available and it is thin.
Specification and result are two columns, and only one of them is a measurement
Statements of conformity are supposed to rest on a stated decision rule. Almost nothing in this trade states one.
FLOW misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Norway declines to reimburse dulaglutide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.